ArticleThe Journal of clinical endocrinology and metabolism2026
Evaluation of the Siemens Healthineers Atellica TSTII testosterone assay in the CDC HoSt-TT program.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundStandardized testosterone measurement is essential for diagnosing hypogonadism, infertility, endocrine disorders, and monitoring therapy. The CDC Hormone Standardization Program for Total Testosterone (HoSt-TT) evaluates assay performance against ID-LC-MS/MS using clinically relevant concentrations. This study assesses the Atellica IM TSTII assay compliance to HoSt-TT criteria and its correlation with LC-MS/MS.
methodsAnalytical performance of Atellica IM TSTII and method comparison studies using HoSt-TT certification samples were analyzed, evaluated, and stratified by sex. Comparisons of TSTII TT to LC-MS/MS and calculated vs measured free testosterone (FT) were performed and analyzed using remnant patient samples, with FT calculated (Vermeulen method, ISSAM calculator).
resultsHoSt-TT vs Atellica IM TSTII assay results demonstrated average bias within ±6.4%, with OLS regression slopes of 1.02-1.06, r ≥ 0.98. TSTII demonstrated repeatability (2.18% CV), within-lab precision (3.46% CV), and overall total analytical error of 18.3% (IQR 11.6-31.6%). Furthermore, comparing TT on the TSTII to LC-MS/MS (LDT) using native patient samples, resulted in strong fits (slope = 0.9798, r = 0.991); and calculated FT correlated well with equilibrium dialysis/LC-MS/MS (slope = 0.9530, r = 0.965).
conclusionThe TSTII assay is CDC HoSt-TT certified, has strong alignment to LC-MS/MS, and shows good correlation of calculated FT with equilibrium dialysis/LC-MS/MS. Although LC-MS/MS remains the reference method for testosterone quantification, particularly at low concentrations, CDC HoSt certification of the TSTII assay supports its potential suitability for measuring testosterone concentrations in women and children within defined analytical and clinical contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.